Physician profile
Robert S Lemons
NPI 1639226459
$633.00
in general payments reported to CMS, 2019-2025
15 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.20 · 2022: $77.12 · 2023: $180 · 2024: $177 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $144.89 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $73.74 | 2022-2023 | |
| Glaxosmithkline, LLC. | $58.51 | 2022-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $51.68 | 2019-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.04 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $44.17 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $39.87 | 2025 | Ozempic, Rybelsus |
| Pfizer INC. | $26.25 | 2024 | |
| Ascend Therapeutics US, LLC | $25.71 | 2023 | |
| Viiv Healthcare Company | $24.44 | 2023 | Dovato |
| Nevro Corp. | $23.36 | 2024 | Senza |
| Dexcom, INC. | $21.62 | 2023 | Dexcom G6 Transmitter |
| Tris Pharma INC | $21.53 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $18.04 | 2025 | Qelbree |
| Amgen INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lemons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.